{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:00:07Z","timestamp":1793059207120,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T00:00:00Z","timestamp":1575590400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"German Federal Ministry of Economics and Technology"},{"name":"Zentrales Innovationsprogramm Mittelstand","award":["ZU4432801MD7"],"award-info":[{"award-number":["ZU4432801MD7"]}]},{"name":"German Federal Ministry of Education and Research"},{"name":"Kleine und Mittelst\u00e4ndische Unternehmen","award":["031B0094A"],"award-info":[{"award-number":["031B0094A"]}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.xphs.2019.10.063","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T17:06:10Z","timestamp":1572714370000},"page":"818-829","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Algorithm-Based Liquid Formulation Development Including a DoE Concept Predicts Long-Term Viral Vector Stability"],"prefix":"10.1016","volume":"109","author":[{"given":"Eva B.","family":"Reinauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella S.","family":"Grosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan R.","family":"Henz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia A.","family":"Rabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Rodenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Altrichter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina F.","family":"Kemter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2019.10.063_bib1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.coi.2011.03.006","article-title":"Viral vectors as vaccine platforms: deployment in sight","volume":"23","author":"Rollier","year":"2011","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.xphs.2019.10.063_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/diseases6020042","article-title":"Viral vectors in gene therapy","volume":"6","author":"Lundstrom","year":"2018","journal-title":"Diseases"},{"key":"10.1016\/j.xphs.2019.10.063_bib3","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/vaccines2030624","article-title":"Developments in viral vector-based vaccines","volume":"2","author":"Ura","year":"2014","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.xphs.2019.10.063_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/protein\/gzq069","article-title":"Virus engineering: functionalization and stabilization","volume":"24","author":"Mateu","year":"2011","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.xphs.2019.10.063_bib5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2011.12.026","article-title":"Coated microneedle arrays for transcutaneous delivery of live virus vaccines","volume":"159","author":"Vrdoljak","year":"2012","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.xphs.2019.10.063_bib6","doi-asserted-by":"crossref","first-page":"13520","DOI":"10.1038\/ncomms13520","article-title":"Additives for vaccine storage to improve thermal stability of adenoviruses from hours to months","volume":"7","author":"Pelliccia","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.xphs.2019.10.063_bib7","unstructured":"JF Wright, G Qu. Compositions and methods to prevent AAV vector aggregation. US Patent Appl US 2,204,721 B2."},{"key":"10.1016\/j.xphs.2019.10.063_bib8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ymthe.2005.02.021","article-title":"Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation","volume":"12","author":"Wright","year":"2005","journal-title":"Mol Ther"},{"key":"10.1016\/j.xphs.2019.10.063_bib9","unstructured":"K Kemter, M Scholz. A novel method for obtaining efficient viral vector-based compositions for vaccination and gene therapy. PCT Int Patent Appl WO 2018\/050872 A1."},{"key":"10.1016\/j.xphs.2019.10.063_bib10","doi-asserted-by":"crossref","first-page":"19ra12","DOI":"10.1126\/scitranslmed.3000490","article-title":"Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrat glass","volume":"2","author":"Alcock","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.xphs.2019.10.063_bib11","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1016\/j.vaccine.2015.08.085","article-title":"Freeze-drying of live virus vaccines: a review","volume":"33","author":"Hansen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.xphs.2019.10.063_bib12","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1016\/j.vaccine.2017.04.086","article-title":"Combined semi-empirical screening and Design of Experiments (DOE) approach to identify candidate formulations of a lyophilized live attenuated tetravalent viral vaccine candidate","volume":"36","author":"Patel","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.xphs.2019.10.063_bib13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/jps.24211","article-title":"Characterization of an oncolytic herpes simplex virus drug candidate","volume":"104","author":"Kumru","year":"2015","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2019.10.063_bib14","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1002\/jps.22618","article-title":"Multidimensional methods for the formulation of biopharmaceuticals and vaccines","volume":"100","author":"Maddux","year":"2011","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2019.10.063_bib15","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4161\/hv.4.5.5863","article-title":"Stabilization of measles virus for vaccine formulation","volume":"4","author":"Kissmann","year":"2014","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.xphs.2019.10.063_bib16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.4161\/hv.3.3.4149","article-title":"High-throughput screening of stabilizers for respiratory syncytial virus. identification of stabilizers and their effects on the conformational thermostability of viral particles","volume":"3","author":"Ausar","year":"2007","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.xphs.2019.10.063_bib17","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1016\/j.vaccine.2011.04.079","article-title":"Towards ambient temperature-stable vaccines. The identification of thermally stabilizing liquid formulations for measles virus using an innovative high-throughput infectivity assay","volume":"29","author":"Schlehuber","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.xphs.2019.10.063_bib18","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/jps.20157","article-title":"Development of stable liquid formulations for adenovirus-based vaccines","volume":"93","author":"Evans","year":"2004","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2019.10.063_bib19","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1016\/j.vaccine.2014.02.033","article-title":"Use of adenovirus as a model system to illustrate a simple method using standard equipment and inexpensive excipients to remove live virus dependence on the cold-chain","volume":"32","author":"Stewart","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.xphs.2019.10.063_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/jps.20496","article-title":"Effect of pH and ionic strength on the physical stability of adenovirus type 5","volume":"95","author":"Rexroad","year":"2006","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2019.10.063_bib21","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/sj.gt.3301527","article-title":"Development of formulations that enhance physical stability of viral vectors for gene therapy","volume":"8","author":"Croyle","year":"2001","journal-title":"Gene Ther"},{"key":"10.1016\/j.xphs.2019.10.063_bib22","doi-asserted-by":"crossref","first-page":"e1700523","DOI":"10.1002\/biot.201700523","article-title":"Amino acid-based advanced liquid formulation development for highly concentrated therapeutic antibodies balances physical and chemical stability and low viscosity","volume":"13","author":"Kemter","year":"2018","journal-title":"Biotechnol J"},{"key":"10.1016\/j.xphs.2019.10.063_bib23","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1369-7021(12)70166-9","article-title":"Nano-coating protects biofunctional materials","volume":"15","author":"Tscheliessnig","year":"2012","journal-title":"Mater Today"},{"key":"10.1016\/j.xphs.2019.10.063_bib24","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/biot.201100494","article-title":"A\u00a0protein-stabilizing technology for enhanced antibody stability and antibody-binding profiles in a microchip array","volume":"7","author":"Scholz","year":"2012","journal-title":"Biotechnol J"},{"key":"10.1016\/j.xphs.2019.10.063_bib25","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.vaccine.2014.01.077","article-title":"Induction of protective immunity against H1N1 influenza A(H1N1)pdm09 with spray-dried and electron-beam sterilised vaccines in non-human primates","volume":"32","author":"Scherliess","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.xphs.2019.10.063_bib26","first-page":"411","article-title":"The stabilization of proteins by osmolytes","volume":"47","author":"Arakawa","year":"1985","journal-title":"Biophysics"},{"key":"10.1016\/j.xphs.2019.10.063_bib27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0169-409X(00)00144-7","article-title":"Factors affecting short-term and long-term stabilities of proteins","volume":"46","author":"Arakawa","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.xphs.2019.10.063_bib28","doi-asserted-by":"crossref","first-page":"9721","DOI":"10.1073\/pnas.122225399","article-title":"Protein-solvent preferential interactions, protein hydration, and modulation of biochemical reactions by solvent components","volume":"99","author":"Timasheff","year":"2002","journal-title":"PNAS"},{"key":"10.1016\/j.xphs.2019.10.063_bib29","first-page":"1148","article-title":"Preferential hydration and the exclusion of cosolvents from protein surfaces","volume":"121","author":"Shimizu","year":"2004","journal-title":"J\u00a0Chem Phys"},{"key":"10.1016\/j.xphs.2019.10.063_bib30","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1002\/jps.22493","article-title":"Evaluation of a non-arrhenius model for therapeutic monoclonal antibody aggregation","volume":"100","author":"Kayser","year":"2011","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2019.10.063_bib31","first-page":"5:001","article-title":"Helper-dependent adenoviral vectors","volume":"2","author":"Rosewell","year":"2011","journal-title":"J\u00a0Genet Syndr Gene Ther"},{"key":"10.1016\/j.xphs.2019.10.063_bib32","series-title":"Charakterisierung adenoviraler Vektoren zur regulierten Expression der BS-RNase","author":"Wirth","year":"2009"},{"key":"10.1016\/j.xphs.2019.10.063_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1099\/vir.0.003087-0","article-title":"Adenoviruses. Update on structure and function","volume":"90","author":"Russell","year":"2009","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.xphs.2019.10.063_bib34","first-page":"5","article-title":"Accelerated titering of adenoviruses","volume":"28","author":"Eyckholt","year":"2000","journal-title":"Biotechniques"},{"key":"10.1016\/j.xphs.2019.10.063_bib36","series-title":"R Foundation for Statistical Computing. v3.6.1.","year":"2019"},{"key":"10.1016\/j.xphs.2019.10.063_bib37","unstructured":"Evans RK, Volkin DB. Adenovirus formulations. US Patent Appl US 7,351,415 B2."},{"key":"10.1016\/j.xphs.2019.10.063_bib38","series-title":"Quality by Design for Biopharmaceuticals. Principles and Case Studies","first-page":"288","volume":"xvi","author":"Rathore","year":"2009"},{"key":"10.1016\/j.xphs.2019.10.063_bib39","unstructured":"Wu Z, Zhang S. Liquid adenovirus formulations. US Patent Appl US 7,888,096 B2."},{"key":"10.1016\/j.xphs.2019.10.063_bib40","unstructured":"Jan J. PCT Int Patent Appl WO 2014\/140645A1."}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235491930735X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235491930735X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:39:06Z","timestamp":1758361146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235491930735X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S002235491930735X"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2019.10.063","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Algorithm-Based Liquid Formulation Development Including a DoE Concept Predicts Long-Term Viral Vector Stability","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2019.10.063","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc. on behalf of the American Pharmacists Association\u00ae.","name":"copyright","label":"Copyright"}]}}